Low-Dose Naltrexone Shows Early Promise for Long COVID Function and Symptoms
A study of 230 adults links low-dose naltrexone to better long COVID symptoms and function, but lacks a control group to establish benefit.
Summary
Low-dose naltrexone was linked to improved symptoms and daily functioning in 230 adults with long COVID, according to research presented at IDWeek. Researchers reviewed clinic records and compared patients’ symptoms before treatment with follow-up visits while taking the drug. A seven-symptom score declined, patients reported fewer symptoms, and functional scores improved. These results matter because long COVID can limit exercise, work, and everyday activities. However, the study had no placebo or untreated comparison group, so it cannot show that naltrexone caused the improvements. Recovery over time, other treatments, and treatment expectations could also explain the changes. The supplied article cuts off before final dosing and safety details. Low-dose naltrexone remains an experimental, off-label option for long COVID that requires clinician guidance and confirmation in randomized trials.
Detailed Summary
Low-dose naltrexone may help some adults with long COVID feel and function better, according to an observational study presented at IDWeek. Persistent symptoms can disrupt work, exercise, and daily life, making potential treatments important for health and physical capacity. However, these findings show an association, not proof that the medication caused improvements.
Researchers reviewed records from 230 adults at the Stanford Long COVID Clinic, comparing symptoms before an off-label naltrexone prescription with subsequent visits during treatment. Median age was 45.4 years, and 67% were women. Treatment began a median of 606 days after infection. Participants needed laboratory-confirmed infection, persistent symptoms, and at least two clinic visits to enter the analysis.
The average seven-symptom score started at 20 and showed an adjusted estimated annual decline of 5.1 points. Symptom counts declined by an estimated 2.4 per year. Functional stage scores improved by 0.32 points annually on a five-point scale, where lower scores indicated better functioning. These changes were statistically significant, but their practical importance remains uncertain for individual patients.
Naltrexone blocks opioid receptors and is approved for alcohol and opioid use disorders. Lower doses are sometimes prescribed for other conditions, and proposed anti-inflammatory effects offer a possible rationale for studying long COVID. This study did not establish that mechanism. Patients considering treatment should discuss uncertainty, medication interactions, and appropriate monitoring with a clinician rather than self-treating.
Crucially, there was no untreated or placebo comparison group, and outcomes were self-reported. Natural recovery, other treatments, expectations, and selection of patients returning for follow-up could explain some improvement. Annualized estimates should not be mistaken for changes directly observed over a full year in everyone. The supplied article ends before reporting final dosing details or safety results. Randomized, placebo-controlled trials are needed to establish whether benefits outweigh harms and identify which patients might benefit most.
Key Findings
- Among 230 adults, the seven-symptom score showed an adjusted estimated annual decline of 5.1 points from a baseline average of 20.
- Symptom counts declined by an estimated 2.4 annually, while functional scores improved by 0.32 points on a five-point scale.
- No control group means natural recovery, treatment expectations, or other therapies could explain the improvements.
- Discuss off-label treatment with a clinician; the supplied report does not establish an effective dose or adequately characterize safety.
Methodology
This MedPage Today news report covers an IDWeek conference presentation describing a retrospective analysis of 230 adults at Stanford. The clinical reporting source is credible, but the evidence is observational, uncontrolled, and based on self-reported outcomes; the supplied text does not establish peer-reviewed publication.
Study Limitations
Without randomization or a comparison group, the study cannot separate medication effects from natural recovery, expectations, concurrent treatments, or selection bias. The supplied article is truncated before final dosing and safety details; verify the conference abstract or primary publication for follow-up duration, adverse events, missing data, and clinical significance.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: